Schwab Charles Investment Management Inc. boosted its holdings in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 7.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 580,149 shares of the biotechnology company’s stock after acquiring an additional 41,860 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.44% of ZIOPHARM Oncology worth $3,609,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. increased its position in shares of ZIOPHARM Oncology by 79.6% during the first quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock worth $239,000 after acquiring an additional 16,700 shares in the last quarter. Creative Planning grew its holdings in shares of ZIOPHARM Oncology by 5.2% during the 2nd quarter. Creative Planning now owns 60,863 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 3,000 shares during the last quarter. American International Group Inc. boosted its position in ZIOPHARM Oncology by 7.1% during the 1st quarter. American International Group Inc. now owns 74,843 shares of the biotechnology company’s stock worth $475,000 after buying an additional 4,951 shares during the period. Cornerstone Capital Management Holdings LLC. acquired a new position in shares of ZIOPHARM Oncology in the 1st quarter worth approximately $510,000. Finally, Parametric Portfolio Associates LLC lifted its position in shares of ZIOPHARM Oncology by 325.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 81,011 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 61,979 shares during the period. Hedge funds and other institutional investors own 41.91% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/28/schwab-charles-investment-management-inc-buys-41860-shares-of-ziopharm-oncology-inc-ziop.html.
Several research firms have commented on ZIOP. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $16.50.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) opened at 4.77 on Friday. The stock’s market cap is $670.81 million. ZIOPHARM Oncology Inc has a 12 month low of $4.40 and a 12 month high of $7.88. The firm’s 50-day moving average price is $5.98 and its 200 day moving average price is $6.17.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. During the same quarter last year, the company earned ($1.01) earnings per share. The company’s revenue for the quarter was down 5.9% compared to the same quarter last year. On average, analysts anticipate that ZIOPHARM Oncology Inc will post ($0.56) earnings per share for the current year.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.